

# PRODUCT INFORMATION



## Indacaterol

Item No. 20070

**CAS Registry No.:** 312753-06-3  
**Formal Name:** 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-2(1H)-quinolinone

**Synonym:** QAB149

**MF:** C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub>

**FW:** 392.5


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 260, 281, 292 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Indacaterol is supplied as a crystalline solid. A stock solution may be made by dissolving the indacaterol in the solvent of choice, which should be purged with an inert gas. Indacaterol is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of indacaterol in these solvents is approximately 1, 15, and 20 mg/ml, respectively.

Indacaterol is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, indacaterol should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Indacaterol has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Indacaterol is a long-acting and selective  $\beta_2$ -adrenergic receptor ( $\beta_2$ -AR) agonist ( $EC_{50} = 8.71$  nM for increasing intracellular cAMP levels *in vitro*).<sup>1</sup> It is selective for  $\beta_2$ -ARs over  $\beta_1$ - and  $\beta_3$ -ARs ( $K_i$ s = 43.6, 616.6, and 3,311.3 nM, respectively). Indacaterol inhibits bronchoconstriction induced by serotonin (5-HT; Item No. 14332) in conscious guinea pigs with a maximal effect of 85% when administered intratracheally at a dose of 6.7  $\mu$ g/kg. It also inhibits bronchoconstriction induced by methacholine (Item No. 23092) in rhesus monkeys with a maximal effect of 75% when administered *via* nebulization at a dose of 12.5 mg/kg. Formulations containing indacaterol have been used alone, and in combination with glycopyrrolate, in the treatment of chronic obstructive pulmonary disease.

### Reference

1. Battram, C., Charlton, S. J., Cuenoud, B., *et al.* *In vitro* and *in vivo* pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled  $\beta_2$  adrenoceptor agonist with a 24-h duration of action. *J. Pharmacol. Exp. Ther.* **317**(2), 762-770 (2006).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/03/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM